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Osteosarcoma is the most common primary malignancy of bone.[1] It is 
relatively rare, however, with an incidence of 4 per million population 
per annum.[1,2] The peak incidence is in the second decade of life, 
with a smaller peak in the 7th and 8th decades, these cases usually 
being secondary.[2-4] The tumour is more common in males than in 
females[5,6] and has a higher prevalence among blacks than among 
whites.[7] The cause is unknown, but individuals with germline 
mutations in the retinoblastoma (Rb) and tumour protein p53 (TP53) 
genes have been shown to be at increased risk.[8,9]
Survival was as low as 5% in the 1950s, with a 5-year survival rate of 
only 22%, most patients undergoing amputation and adjuvant radiation 
only or pioneering chemotherapy.[10] During the 1970s there was a 
marked improvement in 5-year survival rates, which were reportedly as 
high as 81.6% in one study,[11,12] largely owing to significant advances in 
chemotherapy, with utilisation of high-dose and multiagent regimens. 
In addition, tumour necrosis induced by neoadjuvant chemotherapy 
assisted in reducing the size of the surgical margin required for wide 
tumour excision, facilitating successful limb salvage without negatively 
affecting overall survival.[13,14]
Unfortunately, improvements in osteosarcoma management 
that are routine in the developed world are still not common in 
deve loping countries, because of limitations in human resources 
and lack of equipment and access to new and more effective 
chemo therapy regimens. Furthermore, it has been reported that 
cultural beliefs and reliance on traditional medicine in developing 
countries have resulted in late presentation to conventional hospitals, 
resulting in poorer outcomes.[5,15-17] Reliable data from clinical 
outcome and epidemiological studies in developing countries are also 
scarce. [17] Consequently, accurate benchmarking of evidence-based 
management protocols is extremely difficult to achieve. Muthupei 
and Mariba[15] reported a 5-year survival rate of 7.5% in their 2000 
study of 66 osteosarcoma patients at a tertiary hospital in South 
Africa (SA), which is comparable to outcomes from the 1950s in 
developed countries.[10] In 2010, Shipley and Beukes[16] reported 
on 30 patients with osteosarcoma treated at another SA tertiary 
institution. Half of their patients presented with metastases.[16] The 
majority of patients in these studies from developing countries 
presented with advanced disease, to which the authors attributed 
their poor outcomes compared with the far better survival rates in 
developed countries.[5,15-17] Noor et al.[17] had similar findings in a 
study in Cambodia, with a 5-year survival rate of only 8%, citing late 
presentation and cultural preferences as the main factors responsible 
for the poor outcomes.[17]
Objective
To evaluate clinical outcomes of patients with osteosarcoma at 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), a 
tertiary hospital in SA, and compare these with similar studies 
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Background. Osteosarcoma is the most common primary malignant bone tumour. There is a high incidence of late presentation in the 
developing world, posing additional challenges in the treatment of this aggressive disease.
Objective. To evaluate clinical outcomes of patients with osteosarcoma at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), a 
tertiary hospital in South Africa, and compare these with similar studies in the developing world.
Methods. This was a retrospective study of 61 patients treated at CMJAH between 2007 and 2011, with a minimum follow-up of 1.3 years 
(range 1.3 - 6.3).
Results. An average of 4.5 months elapsed before patients were first seen at the CMJAH tumour unit. Fifty-eight patients (95.1%) initially 
sought conventional medical care. Three patients (4.9%) presented with pathological fractures. All the patients underwent biopsy, 
performed an average of 3 weeks after arrival at the tumour unit. In most cases the delay was due to limited access to magnetic resonance 
imaging. Most patients (n=41, 67.2%) were at Enneking stage 2B, 4 (6.6%) were at stage 2A and 16 (26.2%) were at stage 3. Of the patients, 
13 (21.3%) underwent limb salvage procedures, 33 (54.1%) had amputations, 4 (6.6%) refused further treatment and 11 (18.0%) received 
palliative care only; 55 patients (90.2%) received chemotherapy. Two patients developed local recurrence, one of whom had an amputation 
and the other further wide excision. Two patients received palliative radiotherapy. Of the patients, 82.0% were HIV-negative, 4.9% HIV-
positive and the rest of unknown status. At the time of the study, all but two patients, who came from other countries, were traceable or 
known to have died. Our overall 1-year and 5-year survival rates were 62.7% (95% confidence interval (CI) 49.1 - 73.9) and 38.1% (95% 
CI 24.6 - 51.4), respectively. Male patients and those with a higher Enneking stage had a poorer prognosis.
Conclusion. Although most patients sought conventional medical care, unacceptable delays worsened survival. However, our survival 
rates are better than those in other developing countries. We advocate that professional, public and political awareness of osteosarcoma be 
improved as a matter of urgency, to facilitate rapid tertiary referral and expedite management.
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from the developing world to evaluate factors contributing to any 
differences encountered.
Methods
This was a retrospective study of 61 patients treated for osteosarcoma 
at the CMJAH tumour unit over the 5-year period January 2007 - 
December 2011. The minimum follow-up was 1.3 years (mean 3.1, 
range 1.3 - 6.3). CMJAH is a level 1 trauma centre and one of the 
two main teaching hospitals of the University of the Witwatersrand, 
catering not only for the city of Johannesburg but also for Gauteng 
Province and neighbouring provinces and countries. Only patients 
with biopsy-confirmed osteosarcoma were included in the study.
Ethics clearance to conduct the study was obtained from the 
University of the Witwatersrand (ref. no. M150783). The data were 
obtained from theatre registry and patient records. All patients 
admitted to the tumour unit had a comprehensive form (available 
from the first author at lisendal@hotmail.com) completed on 
admission, throughout the course of admission and during follow-
up. The tumour form had three main sections: (i) history and 
clinical findings; (ii) investigations (blood tests and radiography) and 
procedures (biopsy/surgical operations) done; and (iii) follow-up. 
All patients received a standard osteosarcoma work-up consisting of 
blood investigations and imaging before biopsy and then definitive 
treatment. Most patients were followed up at orthopaedic and 
oncology outpatient clinics, and those who had defaulted were 
contacted telephonically.
The main outcome measures were demographics, tumour stage 
according to the Enneking staging system, and treatment options 
offered (surgery (amputation and limb salvage), chemotherapy, 
radiotherapy) and survival. Survival was calculated in years from the 
date of presentation to the time of the study. Kaplan-Meier analysis 
was used to portray survival functions. Equality of survivor functions 
was investigated using the log-rank test.
Results
A total of 61 patients were included in the study (41 males and 
20  females, male/female ratio 2:1). The mean age was 19.4 years 
(range 7 - 48). Most of the patients (n=36, 59.0%) were in their 
second decade, followed by the third decade (n=13, 21.3%) and then 
the first (n=5, 8.2%). The fourth and fifth decades accounted for 4 
(6.6%) and 3 (4.9%) patients, respectively.
Of the patients, 43 (70.5%) and 15 (25.6%) initially sought care 
from their local clinic and general practitioner, respectively, before 
being referred to the tumour unit. Only 3 (4.9%) went to a traditional 
healer before being referred. On average, it took 4.5 months for 
patients to be seen in the tumour unit for the first time. Most patients 
(n=42, 68.9%) were from the CMJAH catchment area of Gauteng 
Province, the other SA provinces and other countries accounting for 
16 (26.2%) and 3 (4.9%), respectively.
The majority of the patients (n=58, 95.1%) presented with a painful 
swollen limb and the rest (n=3, 4.9%) with pathological fractures. 
The tibia was the most common site of involvement, accounting for 
30 cases (49.2%), with the femur and humerus accounting for 19 
(31.1%) and 12 (19.7%), respectively. Only 3 patients (4.9%) were 
HIV-positive; 8 (13.1%) were of unknown status, and the rest (n=50, 
82.0%) were HIV-negative.
Biopsy was done at a mean of 3 weeks after presentation. In most 
cases, the delay was because magnetic resonance imaging (MRI) was 
not readily available. The majority of the patients (n=41, 67.2%) were at 
Enneking stage 2B, 4 (6.6%) were at stage 2A, and 16 (26.2%) presented 
with metastases (stage 3). Conventional osteosarcoma was the most 
common histological type, accounting for 93.4% of cases (Table 1).
In 46 cases (75.4%) surgery was undertaken with the aim 
of achieving wide local resection margins (Table 2). Of these 
46 patients, 13 (28.3%) had limb salvage procedures and 33 (71.7%) 
had amputations. Four patients (6.6%) refused any form of treatment 
despite multidisciplinary counselling and were discharged from the 
hospital for home-based care, and the rest (n=11, 18.0%) received 
palliative care (palliative care only without amputation) because 
they presented late (these included two patients who received 
radiotherapy).
Fifty-five patients (90.2%) received chemotherapy. Of these, 52 
(94.5%) had both neoadjuvant and post-adjuvant chemotherapy and 
3 (5.5%) post-adjuvant chemotherapy only. Palliative radiotherapy 
was administered to 2/61 patients (3.3%) who were not fit for surgery. 
Two patients developed local recurrence, of whom one was treated 
with amputation and the other with further excision.
At the time of the study, 59 patients (96.7%) were traceable or 
known to have died. The two untraceable patients were from other 
countries and had been referred home for further treatment after 
limb salvage. Of the patients who were alive (25/59, 42.4%), 10/13 
(76.9%) had been treated with limb salvage and 14/33 (42.4%) with 
amputation, and the rest (1/4, 25.0%) had refused surgery. Of the 
34/59 patients who were dead, 1/11 (9.1%) had been treated with 
limb salvage and 19/33 (57.6%) with amputation, and 3/4 had refused 
surgery (Table 2). Of the 13/61 patients (21.3%, including the two 
untraceable patients) who defaulted from follow-up or had refused 
treatment, 3/13 (23.1%) had been treated with limb salvage and 9/33 
with amputation (27.3%).
Our 1-year survival rate was 62.7% (95% confidence interval 
(CI) 49.1 - 73.9) and our 5-year survival rate 38.1% (95% CI 24.6 - 
51.4) (Fig. 1). Fig. 2 shows that there was a statistically significant 
Table 1. Histological typing (World Health Organization 
classification) (N=61)









Small cell, low-grade surface, secondary 0
Table 2. Survival v. treatment options
Limb salvage Amputation Palliative Refused treatment Total
Alive 10 14 0 1 25
Dead 1 19 11 3 34
Unknown 2 0 0 0 2
Total 13 33 11 4 61
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difference between the survival curves for the two sexes (p=0.009) as 
calculated by the log-rank test, with males being worse off. However, 
survival according to time (in months) before arrival at CMJAH did 
not differ significantly (p=0.587) (Fig. 3).
All the patients who were staged as Enneking 2A were alive at 
5 years (range 5.08 - 6) without recurrences. Patients with Enneking 
stage 2B disease had 1-year and 5-year survival rates of 69.2% (95% 
CI 52.2 - 81.2) and 47.9% (95% CI 30.4 - 63.4), respectively. For patients 
with Enneking stage 3 disease, the 1- and 5-year survival rates were 
37.5% (95% CI 15.4 - 59.7) and 3.75% (95% CI 0.06 - 23.4), respectively 
(Fig. 4). This difference is statistically significant (p=0.0008).
Only one patient who refused treatment was alive, 24 months 
after discharging herself from the hospital. She had presented with 
a 9-month history of a painful swollen knee and was subsequently 
diagnosed with conventional osteosarcoma of the proximal tibia, 
Enneking stage 2B.
Only one of the three patients who initially presented with a 
pathological fracture was alive, without recurrence at 54 months. 
She was a 12-year-old girl who had a pathological fracture of the left 
proximal tibia and was treated with above-knee amputation (AKA).
Discussion
Our 1-year and 5-year overall survival rates of 62.7% and 38.1% 
are better than those in previous published studies from developing 
countries.[15-17] Muthuphei and Mariba’s[15] SA study in 2000 had 
1- and 5-year survival rates of 25.8% and 7.5%, while Noor et al.[17] 
reported 1- and 5-year survival of 53.6% and 8% in Cambodia. [15,17] 
Our 5-year survival figure is worse than the corresponding figures for 
developed countries, which average >50%.[18-20] Several factors may 
account for our relatively poor outcomes. Our patients presented on 
average 4.5 months after the onset of symptoms, with Enneking stages 
2B and 3 accounting for a combined 93.4% compared with 6.6% 
with stage 2A. The delays may be attributable to poor accessibility 
of health facilities, especially for individuals living in rural areas. 
The higher the Enneking stage on presentation the poorer the 
prognosis, as has been reported in the literature[12] and shown by our 
results. Although only 4.9% of patients admitted to first attending 
a traditional healer, most patients would have consulted them, as 
evidenced by the presence of ‘traditional’ scarifications. Almost a 
third of the patients came from outside our catchment area, which 
could have led to delays in referral. Limited access to MRI in our 
hospital, leading to a further average delay of 3 weeks, exacerbated 
the situation. Biopsies were done approximately a week after the 
MRI and other investigations were completed, resulting in an overall 
mean time to diagnosis of 23.5 weeks. In contrast, the median time 
to diagnosis in developed countries has been reported as 9 weeks. [21] 
Patients from rural areas depend on doctors in district hospitals 
having a high index of suspicion of ‘painful limbs’ and doing initial 
investigations (X-rays) of the affected limb. Improving awareness 
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Fig. 3. Overall Kaplan-Meier survival estimates by time that elapsed before 
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Fig. 4. Overall Kaplan-Meier survival estimates by Enneking stage.
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particular, could increase early referral to specialised tumour units 
and hence the cure rate.
Amputees had poorer survival rates than patients who underwent 
limb salvage, because they had more advanced disease. Amputation 
was offered as ‘palliation surgery’ to relieve malaise and for pain 
control. More amputees than patients who had undergone limb 
salvage defaulted from follow-up at outpatient clinics (orthopaedic 
and oncology), despite multidisciplinary emphasis in hospital on 
surveillance for recurrence, which could explain their poor outcome. 
Preservation of the limb with limb salvage procedures, and hence a 
better self-image, could be a factor explaining the good attendance 
by these patients.
The majority of our patients (95.1%) presented with a painful 
swollen limb and the rest with pathological fractures. Histological 
conventional osteosarcoma accounted for 93.4% of cases, while the 
rest (periosteal, pariosteal and telangiectatic) accounted for 6.6%, 
as shown in Table 1. The incidence of pathological fractures is 
reported to be 5 - 10% in the literature.[22-24] Historically, pathological 
fractures were treated by amputation because of damage to the 
microcirculation that would result in contamination of adjacent 
soft tissue and metastasis.[21] Several authors have since shown that 
there is no difference in terms of survival between patients who have 
amputation and those who have limb salvage.[22,24,25] Three patients 
in our study presented with pathological fractures. Two of these 
patients, who had pathological fractures of the distal femur, had 
metastases and died in hospital from advanced disease. One patient, 
who was unfit for surgery, died few days after admission and the other 
patient, who underwent AKA, 2 months after admission. The only 
patient with a pathological fracture who survived was a 12-year-old 
girl with high-grade osteosarcoma of the left distal tibia. She received 
neoadjuvant and post-adjuvant chemotherapy and was offered AKA 
because the tumour encapsulated the neurovascular structures. She 
was alive and free of disease free 54 months after AKA. Most of our 
patients presented with advanced disease precluding limb salvage.
Just over a quarter of our patients presented with metastases on 
admission. Our 5-year survival of 3.75% for this cohort of patients is 
very low compared with the mid-20s - 30% in developed countries, 
which is attributable to late presentation.[12]
One of the four patients who refused chemotherapy and surgery 
was traceable and alive 24 months after discharging herself. She 
was a 20-year-old woman with high-grade osteosarcoma of the left 
proximal tibia, Enneking stage 2B. She was being looked after by 
relatives at home.
Study limitations
Although 96.7% of our patients were traceable (or known to have 
died) at the time of the study, ~20% of them had defaulted from 
follow-up. This is a major limiting factor in our study. This high 
default rate could be due to difficulty in accessing our facility, and 
also to the fact that ~30% of our patients came from other provinces 
and countries. The majority of those who had defaulted cited lack of 
funds as the reason for not attending. Attempted telephonic contact 
of the two patients from other countries was unsuccessful as the 
numbers were not in use. Another limiting factor is the retrospective 
nature of the study, despite the fact that the data were collected 
prospectively using a comprehensive tumour form.
Conclusion
Treatment of osteosarcoma is challenging, demanding and time-
consuming, and requires meticulous record keeping. Limited 
resources hamper a multidisciplinary approach in developing 
countries. In our setting, both patients and their families need 
extensive education and counselling to improve access to modern 
treatments.
Despite better overall 1-year and 5-year survival rates than in 
other developing countries, our 5-year overall survival rates are 
suboptimal compared with developed countries, mainly because 
of delayed referral and logistical constraints to rapid work-up. We 
strongly recommend improved professional and public awareness 
of the importance of rapid referral, which is vital for the survival of 
these patients.
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